The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and
Wockhardt Limited, a global pharmaceutical company headquartered in India, have partnered to produce and supply Sputnik V and Sputnik Light vaccines against COVID-19.
The agreement was reached under the aegis of Enso Healthcare (part of Enso Group), RDIF's coordination partner for sourcing Sputnik V vaccines in India.
To date, the Sputnik V vaccine has been registered in 69 countries globally with a total population of over 3.7 billion people. The data obtained by regulators of a number of countries during the vaccination of the population, including Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.
The stock is currently trading at Rs513.05 up by Rs23.75 or 4.85% from its previous closing of Rs489.30 on the BSE. The scrip opened at Rs497.45 and has touched a high and low of Rs527 and Rs494.25 respectively.
In particular, Sputnik V demonstrates 83.1% efficacy against the Delta variant of coronavirus - higher than many other vaccines. The vaccine shows 6 times reduction of infection risk. Sputnik V is also 94.4% effective against hospitalisations with 18 times reduction in hospitalisation risk, Wockhardt said.
Dr. Habil Khorakiwala, Founder Chairman of Wockhardt Group, said: “We are delighted to partner with RDIF to make a substantial contribution towards providing global supply of the Sputnik V and Sputnik Light vaccines which is one of the most efficacious approved vaccines commercially available. The arrangement upholds our ongoing commitment to fight against such a pandemic of global human importance.”
Vinay Maloo, Chairman of Enso Healthcare, said: “It is our privilege to partner with RDIF and Wockhardt to facilitate large scale manufacturing of Sputnik V and Sputnik Light vaccines. Vaccinations are the most visible solution to this pandemic. We are proud to be a part of this noble cause. Sputnik V is known to have high efficacy and has emerged as a trusted vaccine.”